Nuclea Energy to go public via $0M Mangoceuticals deal for microreactor
**A Canadian advanced nuclear developer is taking a faster route to the public markets, betting that surging AI-driven electricity demand will accelerate demand for factory-built microreactors.**
Nuclea Energy Inc., a Mississauga, Ontario-based developer of the Morpheus lead-cooled microreactor, has entered into a definitive business combination agreement with Mangoceuticals Inc. (NASDAQ: MGRX), a men's health telemedicine company, the companies said July 30. The deal gives Nuclea a Nasdaq listing without a traditional IPO, at a time when U.S. electricity demand is projected to rise sharply after two decades of being largely flat.
"The scale of capital being committed to power the AI build-out is enormous, and we believe advanced nuclear and microreactors will be a critical part of how that demand is met," Jacob Cohen, chief executive officer of Mangoceuticals, said in a statement.
The Morpheus reactor is a lead-cooled, graphite-moderated design in the conceptual stage, scalable from 3.5 MWe to 50 MWe. Its lead coolant operates at near-atmospheric pressure with a high boiling point, enabling passive natural-convection cooling that requires no pumps — a safety feature that eliminates the need for water or steam inside the reactor. Nuclea has developed a patent-pending annular fuel configuration designed to extend refueling cycles to as long as five years, compared with the industry standard of 1.5 years. The core module, roughly 3 cubic meters, is designed for factory fabrication and transport via standard rail and road shipping.
The transaction structure includes a Nasdaq cap limiting the combined economic and voting rights of Nuclea shareholders to 19.99% of Mangoceuticals' outstanding common stock until stockholder and Nasdaq approvals are obtained. Following those approvals, the exchangeable shares will convert to full voting and economic rights. Joseph Gunnar & Co. is serving as exclusive financial advisor.
**Policy tailwinds and data center demand**
The advanced nuclear sector is benefiting from significant U.S. policy support. The bipartisan ADVANCE Act, signed into law in July 2024, directs the Nuclear Regulatory Commission to develop microreactor-specific licensing guidance within 18 months, reduces fees for advanced reactor applicants and authorizes prizes for first movers. The Department of Energy has also re-issued a $900 million solicitation focused on commercial deployment of American-made small modular reactors, with up to $800 million earmarked for first-mover utility-vendor-constructor teams.
These policy measures align with a structural shift in electricity demand. The build-out of artificial intelligence infrastructure and hyperscale data centers is driving a generational expansion in U.S. power consumption. On July 29, Brookfield Asset Management and NextEra Energy announced plans to develop a $100 billion data center campus at a former DOE uranium enrichment site in Paducah, Kentucky, providing more than 1.2 GW of computing capacity and up to 1.8 GW of electricity to the grid, with operations targeted from 2028.
Nuclea's leadership team combines technical and regulatory expertise. Josef Freundorfer, chief executive officer, also serves as president of Nuclear Potential Canada. Dr. Eleodor Nichita, co-founder and head of reactor design, is an associate professor at Ontario Tech University and former president of the Canadian Nuclear Society. The advisory board includes Jay Patel, a former NRC nuclear safety specialist, and Dr. Michael Binder, former president and CEO of the Canadian Nuclear Safety Commission from 2008 to 2018.
The company is pursuing regulatory pathways in Canada through the CNSC Vendor Design Review process and in the United States through NRC Standard Design Approval, with preliminary pre-application engagements completed. Nuclea targets applications across data centers, defense installations, remote mining operations and off-grid communities currently reliant on diesel generation.
**Investment implications**
The transaction positions Mangoceuticals as a de facto nuclear microreactor pure play upon deal completion, giving retail investors exposure to a sector that has historically been accessible only through larger players like NuScale Power (NYSE: SMR) or Oklo Inc. (NYSE: OKLO). Nuclea's Morpheus remains in the conceptual design stage with an 18-month development roadmap toward regulatory and commercial readiness, meaning the company carries significant technology and licensing risk before generating revenue. The closing is expected before required stockholder and Nasdaq approvals are obtained, with a full S-4 registration statement to follow.
This article is for informational purposes only and does not constitute investment advice.
